Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FT4R
|
|||
| Former ID |
DNC001333
|
|||
| Drug Name |
Sivelestat
|
|||
| Synonyms |
127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 3 | [1] | |
| Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 3 | [1] | ||
| Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 3 | [1] | ||
| Pyoderma gangrenosum [ICD-11: EB21] | Phase 3 | [2] | ||
| Rheumatoid arthritis [ICD-11: FA20] | Phase 3 | [1] | ||
| Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 3 | [1], [3] | ||
| Anterior uveitis [ICD-11: 9A96] | Application submitted | [3] | ||
| Axial spondyloarthritis [ICD-11: FA92.0; ICD-10: M45] | Application submitted | [1] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H22N2O7S
|
|||
| Canonical SMILES |
CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O
|
|||
| InChI |
1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24)
|
|||
| InChIKey |
BTGNGJJLZOIYID-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 127373-66-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10234395, 14759000, 17397876, 26758657, 44436677, 50064306, 50998781, 53800789, 57338198, 76715600, 103277098, 103984170, 104379537, 123392712, 125680070, 126682396, 127564958, 134340533, 135065365, 137156953, 137263939, 140115436, 162183567, 163125720, 163688184, 164192385, 164224889, 172821371, 174006339, 178103057, 179149758, 198973808, 204360313, 208264999, 210275598, 210281257, 215775576, 223657139, 226494344, 242501916, 251971107, 252353896, 252356633
|
|||
| ChEBI ID |
CHEBI:135704
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [4] |
| Pancreatic elastase 1 (CELA1) | Target Info | Inhibitor | [5] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203. | |||
| REF 5 | Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.